1.Clinical features and treatment of cervical malignant tumor in young women.
Yu ZHANG ; Keng SHEN ; Jin-song GAO ; Ming WU ; Hui-fang HUANG ; Ling-ya PAN ; Jing-he LANG
Acta Academiae Medicinae Sinicae 2003;25(4):391-395
OBJECTIVETo evaluate clinical characteristics, prognosis, prognostic factors, and the ideal treatment of the young patients with cervical malignant tumor.
METHODSWe analyzed retrospectively 52 cervical malignant tumor patients younger than 35 years (study group) and 45 cervical carcinoma patients older than 50 years (control group) who were admitted in Peking Union Medical College Hospital from 1985 to 2002. The data were analyzed statistically by SPSS10.0. The ovarian functions were evaluated by the questionnaire and the serum sex hormone assay.
RESULTSIn study group, the median age was (31.0 +/- 0.6) years old. The most common clinical symptoms were contact bleeding and irregular bleeding; 55.8% of patients had more than one symptom. HPV positive rate was 20.5%, which was higher than control group significantly (P < 0.05). The percentage of advanced stage (stage II b-stage IV b) of disease in study group and control group were 30.8% and 22.2%, respectively, the difference was significant (P < 0.05). The most common histological type was squamous cell carcinoma (71.2%) in study group, while the percentage of non-squamous cell carcinoma (43.8%) in patients younger than 30 years was much higher than control group (P < 0.05). All the histological type was non-squamous cell carcinoma in the patients younger than 25 years. Histological grade showed that G1, G2, and G3 were 21.2%, 54.5%, and 24.2% respectively in study group. The percentage of bulky cervix (tumor diameter > 4 cm) in study group and control group was 27.9% and 2.7% respectively (P < 0.005). The overall 5-year survival rates were 75.7% in study group, lower than control group (P < 0.05). The COX hazards regression model showed histological type (P = 0.003) and bulky cervix (P = 0.001) were of significant prognostic values.
CONCLUSIONSThere are more advanced stage carcinoma and non-squamous cell carcinoma patients with poor prognosis in study group. The treatment to younger patients should be concerned individually, as well as preservation of reproductive and female endocrine function should be considered.
Adenocarcinoma ; diagnosis ; surgery ; virology ; Adult ; Age Factors ; Carcinoma, Squamous Cell ; diagnosis ; surgery ; virology ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Ovarian Function Tests ; Papillomaviridae ; isolation & purification ; Papillomavirus Infections ; Prognosis ; Regression Analysis ; Retrospective Studies ; Survival Rate ; Uterine Cervical Neoplasms ; diagnosis ; surgery ; virology
2.GnRH Agonist Therapy to Protect Ovarian Function in Young Korean Breast Cancer Patients.
Hyun Jung PARK ; Young Ah KOO ; Young Hyuck IM ; Byung Koo YOON ; DooSeok CHOI
Journal of Korean Medical Science 2010;25(1):110-116
The increased survival of patients with breast cancer has given rise to other problems associated with the complications of chemotherapy. One major complication is premature ovarian failure, an especially harmful outcome for women of reproductive age. This study was performed to evaluate the efficacy of GnRH agonist (GnRHa) treatment on protecting ovarian function in young breast cancer patients (30.59+/-5.1 yr) receiving chemotherapy after surgery. Twenty-two women were enrolled and given subcutaneous injections of leuprolide acetate (3.75 mg) every 4 weeks during chemotherapy. Follow-up laboratory tests (luteinizing hormone [LH], follicle stimulating hormone [FSH], and estradiol) were performed 1, 3, and 6 months after chemotherapy. Menstruation patterns and clinical symptoms were followed up for a mean duration of 35.6+/-1.7 months. FSH and LH levels were normal in all patients 6 months after completing chemotherapy (8.0+/-5.3, 4.4+/-2.7 mIU/mL, respectively). During follow-up, none of the patients complained of menopausal symptoms and 81.8% experienced recovery of menstruation. This report is the first trial of GnRHa as a treatment modality to protect ovarian function during adjuvant chemotherapy in young Korean breast cancer patients.
Adult
;
Antineoplastic Agents/adverse effects/therapeutic use
;
Antineoplastic Agents, Hormonal/therapeutic use
;
Breast Neoplasms/diagnosis/*drug therapy/surgery
;
Combined Modality Therapy
;
Cyclophosphamide/adverse effects/therapeutic use
;
Doxorubicin/adverse effects/therapeutic use
;
Female
;
Follicle Stimulating Hormone/analysis
;
Gonadotropin-Releasing Hormone/*agonists
;
Humans
;
Leuprolide/administration & dosage
;
Luteinizing Hormone/analysis
;
Menstruation
;
Ovarian Function Tests
;
Primary Ovarian Insufficiency/etiology/*prevention & control
;
Republic of Korea
;
Tamoxifen/therapeutic use
;
Time Factors
3.Profile of the Billings Ovulation Method acceptors and use-effectiveness of the method in Korea.
Journal of Korean Medical Science 1989;4(1):29-34
Data from a survey of 200 Billings Ovulation Method acceptors in Korea were used to describe a profile of these natural family planning acceptors, and to calculate use effectiveness rates for twelve months of use among women using the method for avoiding an unplanned pregnancy. The majority of acceptors were women of proven fertility who wanted to limit their family size, and many of them (79%) had previously used a family planning method. Fifty-six percent were Catholics, and those study subjects were above middle income group by Korean annual household income estimates. The mean number of living children the NFP acceptors had was 2.3 +/- 1.4 and the number of children they desired to have was 2.4 +/- 1.4. The cumulative life table rate for unplanned pregnancies at the end of 12 months of use was 7 (+/- 2.5 S.E.) per 100 women, and women ever attending the learning sessions as couples experienced relatively less unplanned pregnancies compared to those women attending the sessions alone.
Adult
;
Family Planning Services/*methods
;
Female
;
Humans
;
Ovulation Detection/*methods